摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-甲基吲唑-5-硼酸 | 590418-08-9

中文名称
1-甲基吲唑-5-硼酸
中文别名
1-甲基引唑-5-硼酸
英文名称
(1-methyl-1H-indazol-5-yl)boronic acid
英文别名
1-methylindazole-5-boronic acid;1-methyl-1H-indazole-5-boronic acid;(1-methyl-1H-indazole-5-yl)boronic acid;(1-methylindazol-5-yl)boronic acid
1-甲基吲唑-5-硼酸化学式
CAS
590418-08-9
化学式
C8H9BN2O2
mdl
MFCD09870052
分子量
175.983
InChiKey
FPZFXDGMBDJLHR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    397.5±34.0 °C(Predicted)
  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.01
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    58.3
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温

SDS

SDS:400f8ee8336994eb481e92c2931f1994
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-Methylindazole-5-boronic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-Methylindazole-5-boronic acid
CAS number: 590418-08-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H9BN2O2
Molecular weight: 176.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

该化合物1-甲基异唑-5-硼酸主要用于科研。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-甲基吲唑-5-硼酸氯化镍二甲氧基乙烷4,4'-二壬基-2,2'-联吡啶 作用下, 以 1,4-二氧六环 为溶剂, 反应 17.0h, 生成
    参考文献:
    名称:
    镍 (II) - 将芳基和杂芳基环硼氧烷催化加成到亚磺胺试剂 TrNSO:亚磺酰胺、磺酰亚胺和伯磺酰胺的催化合成
    摘要:
    我们报告了氧化还原中性 Ni (II) 催化的(杂)芳基环硼氧烷与N-亚磺酰基三苯甲基胺 (TrNSO) 的加成反应。该反应使用由商业、空气稳定的 NiCl 2组合产生的催化剂(Glyme) 和市售的联吡啶配体,并提供亚磺酰胺产品。该反应的范围是使用磺酰亚胺酰胺合成确定的,其中最初形成的亚磺酰胺与廉价且安全的氯化剂三氯异氰尿酸 (TCCA) 进行氧化氯化,以生产磺酰亚胺酰氯作为关键中间体。这些在原位与一系列胺结合以提供磺酰亚胺酰胺。磺酰亚胺酰氯也可以通过水解制成伯磺酰胺,通过氟化物处理制成磺酰亚胺酰氟。这些转化都是使用一锅法实现的。也可以使用未保护的初级亚磺酰胺。对于更大规模的反应,催化剂负载量可以减少到 1 mol%。
    DOI:
    10.1021/jacs.1c08052
点击查看最新优质反应信息

文献信息

  • Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19
    作者:Aurélie Mallinger、Kai Schiemann、Christian Rink、Frank Stieber、Michel Calderini、Simon Crumpler、Mark Stubbs、Olajumoke Adeniji-Popoola、Oliver Poeschke、Michael Busch、Paul Czodrowski、Djordje Musil、Daniel Schwarz、Maria-Jesus Ortiz-Ruiz、Richard Schneider、Ching Thai、Melanie Valenti、Alexis de Haven Brandon、Rosemary Burke、Paul Workman、Trevor Dale、Dirk Wienke、Paul A. Clarke、Christina Esdar、Florence I. Raynaud、Suzanne A. Eccles、Felix Rohdich、Julian Blagg
    DOI:10.1021/acs.jmedchem.5b01685
    日期:2016.2.11
    complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine
    介体复合物相关的细胞周期蛋白依赖性激酶 CDK8 与人类疾病有关,特别是在结肠直肠癌中,据报道它是一种推定的癌基因。在这里,我们报告了109 (CCT251921) 的发现,它是一种有效的、选择性的和口服生物可利用的 CDK8 抑制剂,对 CDK19 具有等效的亲和力。我们描述了一种基于结构的设计方法,导致发现了 3,4,5-三取代-2-氨基吡啶系列,并介绍了物理化学性质分析的应用,以成功降低体内代谢清除率,最大限度地减少转运蛋白介导的胆汁消除,同时保持可接受的水溶性。化合物109提供了体外生化、药代动力学和物理化学性质的最佳折衷,并适用于发展为癌症动物模型。
  • [EN] INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1<br/>[FR] INHIBITEURS DE LA DÉMÉTHYLASE-1 SPÉCIFIQUE DE LA LYSINE
    申请人:QUANTICEL PHARMACEUTICALS INC
    公开号:WO2016003917A1
    公开(公告)日:2016-01-07
    The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了替代杂环衍生物化合物和包含该化合物的药物组合物。所述化合物和组合物对赖氨酸特异性去甲基化酶-1的抑制是有用的。此外,所述化合物和组合物对癌症的治疗是有用的,如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
  • 氨基嘧啶类化合物及其制备方法和应用
    申请人:北京鞍石生物科技有限责任公司
    公开号:CN108707139B
    公开(公告)日:2021-04-06
    本发明涉及氨基嘧啶类化合物及其制备方法和应用。所述氨基嘧啶类化合物具有式I所示的结构:该化合物是一种表皮生长因子受体(EGFR)激酶的抑制剂。本发明还涉及含有这些化合物的药物组合物,它们的制备方法和它们在制备抗肿瘤药物中的应用。
  • Identification and SAR exploration of a novel series of Legumain inhibitors
    作者:Sharon L. Eddie、Aaron Gregson、Emma Graham、Stephanie Burton、Timothy Harrison、Roberta Burden、Christopher J. Scott、Paul B. Mullan、Rich Williams
    DOI:10.1016/j.bmcl.2019.03.019
    日期:2019.6
    This letter describes the development of a series of potent and selective small molecule Legumain inhibitors suitable as chemical probes for in vitro experiments. Our previous research had identified a dipeptide inhibitor utilizing a semi-reversible cyano warhead that generated 2, a cell active inhibitor. This work explores an alternative P2-P3 linker and further SAR exploration of the P3 group which
    这封信描述了一系列有效的和选择性的小分子Legumain抑制剂的开发,这些抑制剂适合用作体外实验的化学探针。我们之前的研究已经确定了一种利用半可逆的氰基战斗部产生的二肽抑制剂,该头可产生2种细胞活性抑制剂。这项工作探索了另一种P2-P3连接子,并进一步探索了P3基团的SAR,从而鉴定了16i,这是一种具有出色的理化特性的高效抑制剂。
  • Redox-Neutral Photocatalytic Cyclopropanation via Radical/Polar Crossover
    作者:James P. Phelan、Simon B. Lang、Jordan S. Compton、Christopher B. Kelly、Ryan Dykstra、Osvaldo Gutierrez、Gary A. Molander
    DOI:10.1021/jacs.8b05243
    日期:2018.6.27
    A benchtop stable, bifunctional reagent for the redox-neutral cyclopropanation of olefins has been developed. Triethylammonium bis(catecholato)iodomethylsilicate can be readily prepared on multigram scale. Using this reagent in combination with an organic photocatalyst and visible light, cyclopropanation of an array of olefins, including trifluoromethyl- and pinacolatoboryl-substituted alkenes, can
    已开发出一种用于烯烃氧化还原中性环丙烷化的台式稳定双功能试剂。三乙基铵双(儿茶酚)碘甲基硅酸盐可以很容易地以多克规模制备。将该试剂与有机光催化剂和可见光结合使用,可以在数小时内完成一系列烯烃(包括三氟甲基和频哪醇硼基取代的烯烃)的环丙烷化反应。该反应对传统的反应性官能团(羧酸、碱性杂环、卤代烷等)具有高度耐受性,并允许聚烯烃化合物的化学选择性环丙烷化。机理研究表明,反应通过快速阴离子 3-exotet 环闭合进行,该途径与实验和计算数据一致。
查看更多